Manju L. Subramanian

Dr. Manju L. Subramanian

Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Eye
Verified
Journal Article
Closed access
PDF file
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian
GAG Abedi
G Abedi
SNSteven Ness
Steven Ness
EAE Ahmed
E Ahmed
MFM Fenberg
M Fenberg
EFE B Feinberg
E B Feinberg

1 December 2009 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian
SNSteven Ness
Steven Ness
GAGelareh Abedi
Gelareh Abedi
EAEdnan Ahmed
Ednan Ahmed
MDMary Daly
Mary Daly
AHAntoun Houranieh
Antoun Houranieh

28 July 2010 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SGSunali Goyal
Sunali Goyal
MLMichael LaValley
Michael LaValley
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian

30 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
DLDean F. Loporchio
Dean F. Loporchio
ETEmily K. Tam
Emily K. Tam
JCJane Cho
Jane Cho
JCJaeyoon Chung
Jaeyoon Chung
GJGyungah Jun
Gyungah Jun
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian
In this study, we compare the vitreous cytokine profile in patients with proliferative diabetic retinopathy (PDR) to that of patients without PDR. The identification of novel cytokines involved in the pathogenesis of PDR provides candidate therapeutic targets that may stand alone or work synergistically with current therapies in the management of diabetic retinopathy. Undiluted vitreous humor specimens were collected from 74 patients undergoing vitrectomy for various vitreoretinal disorders. Quantitative immunoassay was performed for a panel of 36 neuroinflammatory cytokines in each specimen and assessed to identify differences between PDR (n = 35) and non-PDR (n = 39) patients. Levels of interleukin-8 (IL-8), IL-15, IL-16, vascular endothelial growth factor (VEGF), VEGF-D, c-reactive protein (CRP), serum amyloid-A (SAA), and intracellular adhesion molecule-1 (ICAM1) were significantly increased in the vitreous of PDR patients compared to non-PDR patients (p < 0.05). We report novel increases in IL-15 and IL-16, in addition to the expected VEGF, in the human vitreous humor of patients with PDR. Additionally, we confirm the elevation of ICAM-1, VCAM-1, SAA, IL-8 and CRP in the vitreous of patients with PDR, which has previously been described.

19 August 2020 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
APAlexander D. Port
Alexander D. Port
JNJohn G. Nolan
John G. Nolan
NSNicole H. Siegel
Nicole H. Siegel
XCXuejing Chen
Xuejing Chen
SNSteven D. Ness
Steven D. Ness
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian

8 March 2019 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
LWLauren M. Wright
Lauren M. Wright
TSThor D. Stein
Thor D. Stein
GJGyungah Jun
Gyungah Jun
JCJaeyoon Chung
Jaeyoon Chung
KMKate McConnell
Kate McConnell
Manju L. SubramanianManju L. Subramanian
Manju L. Subramanian
Background: The eye may serve as source for diagnostic testing for early detection of Alzheimer’s disease (AD). Examination of amyloid-β (Aβ) and tau protein content in human vitreous and its correlation to neuro-cognition may improve ocular-based AD detection methods. Objective: To evaluate levels of Aβ and tau protein in human vitreous humor and investigate the clinical predictive role of these proteins as early diagnostic markers of AD. Methods: A prospective, single-center, multi-surgeon cohort study. Vitreous humor samples from 80 eyes were measured quantitatively for Aβ 40-42 , pTau, and tTau. Linear regression was used to test associations between AD biomarker levels, Mini-Mental State Exam (MMSE), and serum apolipoprotein E (APOE) allele status, with adjustment for age, sex, and education level of patients. Results: Lower MMSE scores were significantly associated with lower levels of vitreous Aβ 40 ( p = 0.015), Aβ 42 ( p = 0.0066), and tTau ( p = 0.0085), and these biomarkers were not associated with any pre-existing eye conditions. Presence of the ɛ4 allele and the ɛ2 allele approached significance with reduced Aβ 40 level ( p = 0.053) and increased p-Tau level ( p = 0.056), respectively. Conclusion: Patients with poor cognitive function have significantly lower vitreous humor levels of AD-related biomarkers Aβ 40 , Aβ 42 , and tTau. These biomarkers do not correlate with underlying eye conditions, suggesting their specificity in association with cognitive change. This is the first study to our knowledge to correlate cognition with AD-related proteins in the vitreous humor. Results suggest ocular proteins may have a role for early dementia detection in individuals at risk for AD.